NASDAQ$RVMD
REVOLUTION Medicines Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2024 and provided an update on corporate progress.
Revolution Medicines reported its Q2 2024 financial results, with a net loss of $133.2 million and no revenue, as compared to a net loss of $98.3 million and $3.8 million in revenue for the same period in 2023. The company's cash, cash equivalents, and marketable securities totaled $1.59 billion as of June 30, 2024. The company is progressing with its RAS(ON) inhibitor programs, including RMC-6236, RMC-6291, and RMC-9805, and is planning for a Phase 3 study for RMC-6236 in pancreatic cancer.
- Advanced RMC-6236 into monotherapy pivotal trials for pancreatic and lung cancer.
- Expanded the reach of RMC-6236 monotherapy and combinations into earlier lines of therapy.
- Qualified RAS(ON) mutant-selective inhibitors, RMC-6291 and RMC-9805, for late-stage development.
- Appointed Frank Clyburn to the board of directors and expanded the senior management group.
Headline financials
Revenue & EPS history
Revolution Medicines · Revenue · Quarterly
$0
Forward guidance
Revolution Medicines is reiterating the updated projected full year 2024 GAAP net loss guidance that it shared in July 2024 of between $560 million and $600 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million. Based on the company’s current operating plan, the company projects current cash, cash equivalents and marketable securities can fund planned operations into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+0.1%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+6.7%
Avg return
30 days after
42%
11 / 26 earnings
Positive
+11.7%
Q3 2020
Best reaction
-11.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.6% | -2.1% | +1.4% | |
| Q4 2025 | -0.9% | -2.7% | -10.4% | |
| Q3 2025 | +3.5% | +8.0% | +34.2% | |
| Q2 2025 | -4.7% | -3.8% | +10.4% | |
| Q1 2025 | +11.4% | +6.1% | +9.1% | |
| Q4 2024 | -3.5% | -6.3% | -7.8% | |
| Q3 2024 | +4.1% | +6.8% | -15.3% | |
| Q2 2024 | -3.0% | -0.7% | -3.3% | |
| Q1 2024 | -3.7% | -4.4% | +3.8% | |
| Q4 2023 | +3.0% | +0.2% | +6.7% | |
| Q3 2023 | -3.0% | -11.1% | +8.2% | |
| Q2 2023 | -0.1% | +1.2% | +8.3% | |
| Q1 2023 | +3.5% | +6.3% | +10.6% | |
| Q4 2022 | +10.0% | +4.6% | -11.5% | |
| Q3 2022 | -4.1% | +8.1% | +17.8% | |
| Q2 2022 | +0.5% | +4.2% | -11.1% | |
| Q1 2022 | -6.4% | -7.8% | +15.4% | |
| Q4 2021 | -6.4% | -12.7% | +29.1% | |
| Q3 2021 | -1.7% | -2.5% | -24.4% | |
| Q2 2021 | -11.7% | -5.6% | +9.7% | |
| Q1 2021 | +7.1% | +8.2% | +10.7% | |
| Q4 2020 | -9.2% | -1.1% | +1.8% | |
| Q3 2020 | +11.7% | +10.7% | +17.4% | |
| Q2 2020 | +6.9% | -3.8% | +8.3% | |
| Q1 2020 | -1.3% | +0.8% | +4.9% | |
| Q4 2019 | -2.5% | +4.2% | +49.6% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro